Advertisement

© 2018

Resistance to Ibritumomab in Lymphoma

  • Makoto Hosono
  • Jean-François Chatal
Book

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 18)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Yoichi Tatsumi
    Pages 9-31
  3. Takayoshi Ishimori, Koya Nakatani
    Pages 67-77
  4. Kohei Hanaoka, Makoto Hosono
    Pages 99-104
  5. Gerhard Glatting
    Pages 105-117
  6. Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet, Michel Chérel
    Pages 119-137
  7. Clément Bailly, Caroline Bodet-Milin, François Guérard, Caroline Rousseau, Michel Chérel, Françoise Kraeber-Bodéré et al.
    Pages 139-153
  8. Back Matter
    Pages 155-158

About this book

Introduction

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Keywords

Ibritumomab Lymphoma Non-Hodgkin's Follicular B-cell Toxicity

Editors and affiliations

  • Makoto Hosono
    • 1
  • Jean-François Chatal
    • 2
  1. 1.Institute of Advanced Clinical MedicineKindai University Faculty of MedicineOsakaJapan
  2. 2.GIP ArronaxNantes-Saint-HerblainFrance

About the editors

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 


Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Bibliographic information

  • Book Title Resistance to Ibritumomab in Lymphoma
  • Editors Makoto Hosono
    Jean-François Chatal
  • Series Title Resistance to Targeted Anti-Cancer Therapeutics
  • Series Abbreviated Title Resistance to Targeted Anti-Cancer Therapeutics
  • DOI https://doi.org/10.1007/978-3-319-78238-6
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-78237-9
  • Softcover ISBN 978-3-030-08652-7
  • eBook ISBN 978-3-319-78238-6
  • Series ISSN 2196-5501
  • Series E-ISSN 2196-551X
  • Edition Number 1
  • Number of Pages XIII, 158
  • Number of Illustrations 4 b/w illustrations, 14 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology
Consumer Packaged Goods